Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector
Patent
1998-03-18
1999-09-07
Saunders, David
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
424 931, 424520, 424810, 514 2, 514 3, 514 8, 514 21, 530303, 530350, 530383, 530384, A01N 6300, A61K 3837, A61K 3502, A61K 3828
Patent
active
059484071
ABSTRACT:
Disclosed is a method for reducing an immune response to a parenterally administered non-autologous antigen in an individual who is immunologically responsive thereto by mucosally administering to the individual an amount of the antigen effective to reduce any immune response to parenteral administration of said antigen. The antigen can be a polypeptide such as a hormone, like insulin, which supplements a metabolic deficiency in the recipient of a polypeptide intended to serve the same function. The polypeptide can also be one which supplements a deficiency in the production of a physiologically important polypeptide, such as a hematologic regulatory factor. The hematologic regulatory factor can enhance or inhibit thrombogenesis or platelet deposition. Also, the antigen can be a tissue or cell preparation, such as of allogeneic or xenogeneic tissue or cells. The method for reducing an immune response is preferably one which induces tolerance to parenteral administration of the antigen, such as by inducing or elevating a suppressor T cell response to the mucosally administered antigen.
REFERENCES:
patent: 5720955 (1998-02-01), Weiner et al.
patent: 5733547 (1998-03-01), Weiner et al.
patent: 5763396 (1998-06-01), Weiner et al.
patent: 5783188 (1998-07-01), Weiner et al.
Miller, A., et al. (1993) "Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein: V.I. Suppression of adoptively transferred disease and differential effects of oral vs. intravenous tolerization," Journal of Neuroimmunology, 46: 73-82.
Trentham, D.E., et al. (1993) "Effects of Oral Administration of Type II Collagen on Rheumatoid Arthritis," Science, 261: 1727-1729.
Kaufman, D.L., et al. (1993) "Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes," Nature, 366: 69-70.
Weiner, H.L., et al. (1994) "Oral Tolerance: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," Annu. Rev. Immunol., 12: 809-837.
Al-Sabbagh, A., et al. (1994) "Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse," Eur. J. Immunol., 24: 2104-2109.
Khare, S.D., et al. (1995) "Oral Administration of an Immunodominant Human Collagen Peptide Modulates Collagen-Induced Arthritis," The Journal of Immunology, 155: 3653-3659.
Ruedl, C., et al. (1996) "Humoral and cellular immune responses in the murine respiratory tract following oral immunization with cholera toxin or Escherichia coli heat-labile enterotoxin," Vaccine, 14(8): 792-798.
Chen, Y., et al. (1996) "Oral tolerance in myelin basic protein T-cell receptor transgenic mice: Suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells," Proc. Natl. Acad. Sci. USA, 93: 388-391.
Vandenbark, A.A., et al. (1996) "Treatment of multiple sclerosis with T-cell receptor peptides: Results of a double-blind pilot trial," Nature Medicine, 2(10): 1109-1115.
Blanas, E., et al. (1996) "Induction of Autoimmune Diabetes by Oral Administration of Autoantigen," Science, 274: 1707-1709.
Hoyer, Leon W., "Future Approaches to Factor VIII Inhibitor Therapy," The American Journal of Medicine, 91(5A):40S-44S (1991).
Nilsson, et al., "Noncoagulation Inhibitory Factor VIII Antibodies After Induction of Tolerance to Factor VIII in Hemophilia A Patients," Blood, 75(2):378-383 (1990).
Sun, et al., "Cholera toxin B Subunit: An efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance," Proc. Natl. Acad. Sci., 91:10795-10799 (1994).
Weiner, Howard L., "Oral Tolerance," Proc. Natl. Acad. Sci., 91:10762-10765 (1994).
Burnside Beth A.
McGuinness Charlotte M.
Rudnik Edward M.
Olstein Elliot M.
Saunders David
Semionow Raina
Shire Laboratories Inc.
VanderVegt F. Pierre
LandOfFree
Oral induction of tolerance to parenterally administered non-aut does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oral induction of tolerance to parenterally administered non-aut, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral induction of tolerance to parenterally administered non-aut will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1802011